1540 related articles for article (PubMed ID: 24226524)
1. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
[TBL] [Abstract][Full Text] [Related]
2. Knockout of Na
Song P; Huang W; Onishi A; Patel R; Kim YC; van Ginkel C; Fu Y; Freeman B; Koepsell H; Thomson S; Liu R; Vallon V
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F207-F217. PubMed ID: 31091127
[TBL] [Abstract][Full Text] [Related]
3. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
4. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus.
Vallon V; Rose M; Gerasimova M; Satriano J; Platt KA; Koepsell H; Cunard R; Sharma K; Thomson SC; Rieg T
Am J Physiol Renal Physiol; 2013 Jan; 304(2):F156-67. PubMed ID: 23152292
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
Gangadharan Komala M; Gross S; Mudaliar H; Huang C; Pegg K; Mather A; Shen S; Pollock CA; Panchapakesan U
PLoS One; 2014; 9(11):e108994. PubMed ID: 25369239
[TBL] [Abstract][Full Text] [Related]
6. Effect of renal tubule-specific knockdown of the Na
Onishi A; Fu Y; Darshi M; Crespo-Masip M; Huang W; Song P; Patel R; Kim YC; Nespoux J; Freeman B; Soleimani M; Thomson S; Sharma K; Vallon V
Am J Physiol Renal Physiol; 2019 Aug; 317(2):F419-F434. PubMed ID: 31166707
[TBL] [Abstract][Full Text] [Related]
7. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
8. Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?
Panchapakesan U; Pegg K; Gross S; Komala MG; Mudaliar H; Forbes J; Pollock C; Mather A
PLoS One; 2013; 8(2):e54442. PubMed ID: 23390498
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway.
Locatelli M; Zoja C; Conti S; Cerullo D; Corna D; Rottoli D; Zanchi C; Tomasoni S; Remuzzi G; Benigni A
J Pathol; 2022 Apr; 256(4):468-479. PubMed ID: 35000230
[TBL] [Abstract][Full Text] [Related]
10. A role for tubular Na
Onishi A; Fu Y; Patel R; Darshi M; Crespo-Masip M; Huang W; Song P; Freeman B; Kim YC; Soleimani M; Sharma K; Thomson SC; Vallon V
Am J Physiol Renal Physiol; 2020 Oct; 319(4):F712-F728. PubMed ID: 32893663
[TBL] [Abstract][Full Text] [Related]
11. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
Fu Y; Breljak D; Onishi A; Batz F; Patel R; Huang W; Song P; Freeman B; Mayoux E; Koepsell H; Anzai N; Nigam SK; Sabolic I; Vallon V
Am J Physiol Renal Physiol; 2018 Aug; 315(2):F386-F394. PubMed ID: 29412698
[TBL] [Abstract][Full Text] [Related]
12. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.
Kidokoro K; Cherney DZI; Bozovic A; Nagasu H; Satoh M; Kanda E; Sasaki T; Kashihara N
Circulation; 2019 Jul; 140(4):303-315. PubMed ID: 30773020
[TBL] [Abstract][Full Text] [Related]
14. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.
Rieg T; Masuda T; Gerasimova M; Mayoux E; Platt K; Powell DR; Thomson SC; Koepsell H; Vallon V
Am J Physiol Renal Physiol; 2014 Jan; 306(2):F188-93. PubMed ID: 24226519
[TBL] [Abstract][Full Text] [Related]
15. Deletion of heterogeneous nuclear ribonucleoprotein F in renal tubules downregulates SGLT2 expression and attenuates hyperfiltration and kidney injury in a mouse model of diabetes.
Miyata KN; Lo CS; Zhao S; Zhao XP; Chenier I; Yamashita M; Filep JG; Ingelfinger JR; Zhang SL; Chan JSD
Diabetologia; 2021 Nov; 64(11):2589-2601. PubMed ID: 34370045
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in
Korbut AI; Taskaeva IS; Bgatova NP; Muraleva NA; Orlov NB; Dashkin MV; Khotskina AS; Zavyalov EL; Konenkov VI; Klein T; Klimontov VV
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340263
[TBL] [Abstract][Full Text] [Related]
17. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
[TBL] [Abstract][Full Text] [Related]
18. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
[TBL] [Abstract][Full Text] [Related]
19. The tubular hypothesis of nephron filtration and diabetic kidney disease.
Vallon V; Thomson SC
Nat Rev Nephrol; 2020 Jun; 16(6):317-336. PubMed ID: 32152499
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
van Bommel EJM; Muskiet MHA; Tonneijck L; Kramer MHH; Nieuwdorp M; van Raalte DH
Clin J Am Soc Nephrol; 2017 Apr; 12(4):700-710. PubMed ID: 28254770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]